Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: mutations present in more than 90% of cases. Daraxonrasib is an oral RAS(ON) multiselective, tri-complex inhibitor of the active guanosine triphosphate-bound state of mutant and wild-type RAS. METHODS: G12 and overall populations. Safety was also assessed. RESULTS: G12 population was 7.3 months with daraxonrasib and 3.5 months with chemotherapy, and that in the overall population was 7.2 months and 3.6 months, respectively; the hazard ratios were 0.45 and 0.49, respectively (P<0.001 for both comparisons). Adverse events that occurred after the start of treatment were reported in all the patients in the daraxonrasib group and in 97.7% of those in the chemotherapy group; the incidence of adverse events of grade 3 or higher was 61.8% and 69.6%, respectively. Treatment-related adverse events that led to treatment discontinuation occurred in 1.2% of the patients in the daraxonrasib group and in 11.2% of those in the chemotherapy group. CONCLUSIONS: Among patients with previously treated mPDAC, treatment with daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. (Funded by Revolution Medicines; RASolute 302 ClinicalTrials.gov number, NCT06625320.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this trial, daraxonrasib significantly improved overall survival and progression-free survival compared with chemotherapy.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [59]
In the citing paper
“In the overall population, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy, and median progression-free survival was 7.2 versus 3.6 months, respectively.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [59]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Integrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019
Park, W., Chawla, A., & O’Reilly, E. M. (2021) · JAMA · doi:10.1001/jama.2021.13027 · Cited by 1,882
Self-citationPancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Conroy, T., Pfeiffer, P., Vilgrain, V., Lamarca, A., Seufferlein, T., O’Reilly, E. M., Hackert, T., Golan, T., Prager, G., Haustermans, K., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.009 · Cited by 610
Self-citationWainberg, Z. A., Melisi, D., Macarulla, T., Pazo Cid, R., Chandana, S. R., De La Fouchardière, C., Dean, A., Kiss, I., Lee, W. J., Goetze, T. O., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01366-1 · Cited by 516
Self-citationMultidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Grossberg, A. J., Chu, L. C., Deig, C. R., Fishman, E. K., Hwang, W. L., Maitra, A., Marks, D. L., Mehta, A., Nabavizadeh, N., Simeone, D. M., et al. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21626 · Cited by 489
Therapeutic developments in pancreatic cancer
Hu, Z. I., & O’Reilly, E. M. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 413
Self-citation
Research works printed but not linked: 1
- Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin 2026;76(1):e70043-e70043.41528114
Cited by
Items 101–200 of 226
dos Santos, L. M., Bialves, T. S., Bastos, L. L., Silva, J. G. D. M., Araújo, S. C., Melo, J. D. O., Sabino, A. D. P., Tarazona-Santos, E., de Lima, L. H. F., Rocha, G. B., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10671907/v1
Survivin Promotes the Formation of a Microtubule-Based Glycolytic HubPreprint
Neumann, J., Chang, W.-H., Ackermann, S. E., Zanotelli, M. R., Markovich, T., 杨闰英, Lefkowitz, J. R., Enomoto, S., Le, H. H., Lee, M.-T., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.28.747899
The Times They Are A-Changin’: Pancreatic Cancer Surgery in the RAS Inhibitor Era
Tiriac, H., & Lowy, A. M. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20525-3
Akgüner, G., Benlioglu, E. H., Yıldırım, Ö. A., İlhan, A., Günel, B., Arıkök, A. T., Öksüzoğlu, Ö. B. Ç., & Yucel, K. B. (2026) · Cancers · doi:10.3390/cancers18172827
Li, L., Li, J., Yang, L., Zhou, J., & Ma, Y. (2026) · Pharmaceuticals · doi:10.3390/ph19091388
Landmark pancreatic cancer drug shows potential against lung cancer too
Ledford, H. (2026) · Nature · doi:10.1038/d41586-026-02745-5
What a wonderful world: beyond relapsed pediatric acute myeloid leukemia
Tomizawa, D. (2026) · Haematologica · doi:10.3324/haematol.2026.301786
DaSilva, B. A., Neugut, A. I., Fojo, T., & Bates, S. E. (2026) · The Oncologist · doi:10.1093/oncolo/oyag354
Equity in expanded access programs for daraxonrasib
Ulitin, A. M., & Fenig, S. (2026) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2026.100807
RAS-targeted therapies for pancreatic cancer
Chan, L. L., Kwong, T. T., Yau, J., & Chan, S. L. (2026) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2026.100414
Reflecting on 25 years of cancer research: transformative advances and unmet expectations
Balmain, A., Bernards, R., Clevers, H. C., Vousden, K. H., Workman, P., & Žitnik, M. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00974-4
Wang, E., Yao, A., Sasaki, M., Tanaka, R., Hassanein, M., Fujiwara, Y., & Tokuhara, T. (2026) · Journal of Clinical Question · doi:10.69854/jcq.2026.0026
KRAS Q61 NSCLC: When Alleles Matter
Prina, M. M., & Mezquita, L. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-2135
Ibrahim, M. L., Foresman, D., Zheng, H., Liu, X., Xie, M., Boyle, T. A., Johnson, J., Rodríguez, P. C., Abate‐Daga, D., Ruffell, B., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-26-0213
Gao, P., & Zhang, J. (2026) · LabMed discovery. · doi:10.1016/j.lmd.2026.100144
Pancreatic ductal adenocarcinoma: Clinical trials to watch
Groot, V. P., Molenaar, I. Q., Cirkel, G. A., Wolfgang, C. L., & van Santvoort, H. C. (2026) · Med · doi:10.1016/j.medj.2026.101268
Lanthier, L., Pool, G., Mutchmore, A., Plourde, M.-É., & Cauchon, M. (2026) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2026.08.016
Tan, R., Zhang, Z., Wang, J., Andersson, R. E., Ansari, D., & Chen, J. (2026) · Clinical and Translational Discovery · doi:10.1002/ctd2.70202
Pancreatic ductal adenocarcinoma: The Vision of Heracles
Reyes, C. M., Goetz, M. R., Algül, H., Dogruoez, A., Falcomatà, C., Gaida, M. M., Görgülü, K., Gültekin, Y., Gürçınar, İ. H., Hasselluhn, M. C., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.07.014
The dawn of RAS-targeted therapy: a landmark breakthrough of daraxonrasib in pancreatic cancer
Liu, C., & Liu, L. (2026) · Clinical Cancer Bulletin · doi:10.1007/s44272-026-00072-4
Advances in KRAS-Targeted Therapies for Pancreatic Cancer
Peshin, S., Zahid, A., Takrori, E., Hamedi, Z., & Rahman, S. (2026) · Cancers · doi:10.3390/cancers18182961
Ikezawa, K., Imai, T., Takada, R., Yamai, T., Fukutake, N., Urabe, M., Kai, Y., Mukai, K., Nakabori, T., & Ohkawa, K. (2026) · Cancer Reports · doi:10.1002/cnr2.70691
Song, Z. (2026) · Transactions on Materials Biotechnology and Life Sciences · doi:10.62051/ndcdrx21
The future of integrated treatment for PDAC: Learning from the past, advancing for the better
Maekawa, A., Marchegiani, G., & Capurso, G. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.09.002
Beyond the breakthrough for RAS-driven cancers
King, R. E. C., Tsang, E. S., & Knox, J. J. (2026) · Nature Medicine · doi:10.1038/s41591-026-04610-4
Nakamura, T., Ohishi, T., Kaneko, M. K., Suzuki, H., & Kato, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms272210317
Difluoromethylornithine modulates mutant K-RAS signaling pathways in pancreatic cancer cells
Chen, H., Stringer, D. E., Cui, H., Gerner, E. W., & Ignatenko, N. A. (2026) · Amino Acids · doi:10.1007/s00726-026-03559-5
Grados, L., Rhaiem, R., Amroun, K., Zimmermann, P., Deguelte, S., Gigante, E., Bouché, O., & Kianmanesh, R. (2026) · Cureus · doi:10.7759/cureus.116374
PADI-dependent mitochondrial adaptation drives resistance to KRAS inhibitors
Gani, M., Agostini, F., Secco, L., Pino, L. D., Picco, R., Licastro, D., Tolotto, V., D’Este, F., Choudhary, H., Ferino, A., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.118016
Chen, S., Xie, Y., Xu, S., Su, L., Xu, Y., Liu, S., Zheng, Q., Liu, Q., & Sun, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1908017
Esmail, A., Guan, J., Alabed, Z., Hamdaneh, Y., Al-Najjar, E., Abdelrahim, S., Mustafa, N., Khasawneh, B., & Abdelrahim, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1902839
Han, S., Starasvetskaya, N., Terrero, G., Hosein, P. J., & Lopes, G. D. L., Jr. (2026) · medRxiv · doi:10.64898/2026.09.16.26363246
Neoantigen-reactive CD8 + T cell engagement marks exceptional survivors of pancreatic cancerPreprint
Hilmi, M., Schoenfeld, J. D., McKerrow, W., Elhanati, Y., O’Connor, C. A., Umeda, S., Lecomte, N., Melchor, J. P., Cardenas, A., Lao, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.17.752426
Self-citationSuicide Risk and Associated Factors in Patients with Pancreatic Cancer: A Systematic Review
Chicoisneau, M., Bouchart, C., & Hein, M. (2026) · Diseases · doi:10.3390/diseases14090346
Targeting RAS for Pancreatic Cancer Interception
Misale, S., Zaidi, N., Jaffee, E. M., Klein, A. P., & Wood, L. D. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-26-1179
Debien, V., Cremieux, A. G., Grand, M. L., Carbone, D., Garajová, I., Pecoraro, C., Pasquier, E., Peters, G. J., Giovannetti, E., Centanni, M., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108576
Williams, C. M., Patel, R. A., Lisek, N. A., Kakarala, C. L., Cavnar, M. J., Kim, J., Pandalai, P. K., Baiyee, E., Castria, T. B. D., Manne, A., et al. (2026) · medRxiv · doi:10.64898/2026.09.22.26363302
Current landscape of RAS-targeted therapy for pancreatic cancer
Wu, Y. L., Herzberg, B., & Manji, G. A. (2026) · The Oncologist · doi:10.1093/oncolo/oyag379
Self-citationSun, Y., Pang, C., & Gao, J. (2026) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2026.01067
Gierulska, N., Jankowska, N., Dąbrowska, Z., Piekarz, J., & Skórzewska, M. (2026) · Cancers · doi:10.3390/cancers18193112
Metastatic pancreatic cancer: from human disease to preclinical modelling
Min, J., Liaki, V., Yu, P. Y., Guerra, C., & Maitra, A. (2026) · Gut · doi:10.1136/gutjnl-2025-336334
Kajitani, T., Huang, F., Nishiura, K., Irwin, D., Chein, A., & Fujinaga, K. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.26.754677
Muhammad, M., Khinji, A. A., Al-Ansari, M., Al-Marri, N., Al-Shaheen, S., & Malouche, D. (2026) · Cancers · doi:10.3390/cancers18193139
Shaker, P., Kamran, D., Du, L., Pant, S., Rogers, J. E., & Mizrahi, J. D. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01601-z
Self-citationWang, S., Boeck, A. D., Kang, E. Y., Meagher, N. S., Gorringe, K. L., Nelson, G. S., Lee, C. H., Minoo, P., & Köbel, M. (2026) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000001219
Zelenai, F., Bakos, E., Süller-Torma, V., Dank, M., Madurka, I., & Horváth, O. (2026) · Cancers · doi:10.3390/cancers18193127
Harnessing novel agents to target KRAS-driven pathways in pancreatic cancer
Kreidi, J., Hoyek, C., Eslinger, C. R., & Bekaii-Saab, T. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2738708
García‐Carbonero, R., Pazo-Cid, R., Macarulla, T. M., Laquente, B., Nguyen, A., Guillén‐Ponce, C., Munoz, A., Kim, E. J.-H., Cazorla, M., Tara, S., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04705-y
Gribbin, K. P., Halamish, H., Siordia, I. R., Finan, J. M., Pishvaian, M. J., Lopez, C. D., Kardosh, A., Goodyear, S. M., Sears, R. C., Zimmers, T. A., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218864
Special Issue “Molecular Mechanisms and Therapies of Pancreatic Cancer: 2nd Edition”
Vilardo, C., Domenico, A. D., & Cave, D. D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198735
Cook, L., Prue, G., McShane, C., Krishnasamy, M., Furness, K., McLaughlin, S. B., & Mitchell, G. (2026) · Cancers · doi:10.3390/cancers18193177
DeLiberty, J. M., Kong, F. Y., Yu, Q., Sindoni, N., Lin, J., Kang, K., Kim, E. Y., Chen, S., Padhye, A., Coker, O., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.01.756025
Stańczak, M., & Niazi, S. K. (2026) · Pharmaceuticals · doi:10.3390/ph19101578
Precision Cancer Prevention – Research Promise and Education Needs
Faupel‐Badger, J. M. (2026) · Journal of Cancer Education · doi:10.1007/s13187-026-02997-9
Coriat, R. (2026) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2026.100849
Yamamoto, N., Dobersch, S., Robertson, T. M., Sim, J. H., Wallace-Povirk, A., Chew, N. W., Orellana, A. E., Aggrey-Fynn, J. E., Boila, L. D., Schutter, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.02.754697
Current and future therapies for acute myeloblastic leukemia
Marvin‐Peek, J., & Ravandi, F. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01849-9
Klinische Studien beim Pankreaskarzinom: aktuelle Strategien und laufende Studien
Schuh, F., Jenzer, M., Springfeld, C., & Klotz, R. (2026) · Die Onkologie · doi:10.1007/s00761-026-02032-y
Self-citationWoodcock, J., Pierce, A. J., Drescher, C. W., Leib, J. R., Jafri, M. S., Rader, D. J., Schreier, J., Ramage, J., Ramsey, S. D., Dumanois, R. H., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00797
The impact of sex and ancestry on the molecular landscape of pancreatic adenocarcinomaPreprint
Chen, C. Y., Arbet, J., Zhu, C., Oh, J., & Boutros, P. C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.06.757201
Tran, T. T., Nguyen, H. P. U., Fahrmann, J. F., Pham, D. T., Bui, L., Bui, N. H., & Schmidt, C. M. (2026) · medRxiv · doi:10.64898/2026.10.02.26364030
Targeting SERPINB5 and MSLN for Pancreatic Cancer Therapy
Sun, J., Liu, L., Broadhurst, R., Wang, D., Mehta, A., Guttridge, D. C., Ferreira, L. M. R., Wang, H., & Gao, X. (2026) · Cancers · doi:10.3390/cancers18193242
Sinan, H., Sleiman, E. A., Blackford, A. L., Shinozuka, T., Melki, D., Saab, J., Romanos, M., Ning, K., Almardini, M., Castellino, A., et al. (2026) · Pancreatology · doi:10.1016/j.pan.2026.10.013
Beyond target presence: A cross-cancer contextual framework for siRNA therapeutics in solid tumors
Zhao, N., Zhang, Y., Qian, C., 张华巍, & Wang, L. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189732
Self-citationLee, J. H., Shin, K., Hong, T. H., Kim, I.-H., Hong, S. H., Lee, M. A., & Park, S. J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15207789
Blockade of mutant RAS oncogenic signaling: A 2026 update
Roskoski, R. J. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.109669
Sewell, P. E. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1941793
Subbiah, V., & Kurzrock, R. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01216-0
Emerging therapeutic targets and early-phase drug development in gynecological malignancies
Ouali, K., Tan, D., Lheureux, S., & Massard, C. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.10.101
Contemporary systemic therapy of medullary thyroid cancer
Abdel-Rahman, O. M. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2749641
Strategies to develop therapeutic cancer vaccines for pancreatic cancer
Coppi, M. M., Graciotti, M., Digklia, A., & Kandalaft, L. E. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00149-4
Targeting (K)RAS in pancreatic ductal adenocarcinoma—ASCO 2026 highlights
Windhager, H., & Doleschal, B. (2026) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-026-01133-z
Rosenstein, B. S., & Karp, J. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13468-5.00004-7
Stupan, U. (2026) · Repository of the University of Ljubljana (University of Ljubljana)
Nickerson, J. L., Condon-Oldreive, S., Tsang, E. S., Zogopoulos, G., Ouellette, R. J., Haçarız, O., Antón-Pascual, B., Serrano, P. E., Gill, S., Vareki, S. M., et al. (2026) · Current Oncology · doi:10.3390/curroncol33100629
Gaur, K. S., Hall, W. A., Kamgar, M., McFall, T. B., Evans, D. B., & Seo, Y. D. (2026) · Cancers · doi:10.3390/cancers18203376
Sample, J. W., Özmert, E., Wilbanks, B. A., Carlson, D. M., Nishi, H., Abdelrahman, A. M., Jessen, E., Cai, M., Mun, D., Kuipers, H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.18.759975
Self-citationBryan, A., Pangeni, R., Akakpo, J. Y., Wendling, A., Isbell, M., Martin, R., Weistroffer, G., Jaeschke, H., Ingabire, D., Lee, W. S., et al. (2026) · Cancers · doi:10.3390/cancers18203390
Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
O'Reilly, E. M., Wolpin, B. M., & Wainberg, Z. A. (2026) · New England Journal of Medicine · doi:10.1056/nejmc2611022
Self-citationTozandehjani, S., Jurjevič, V., Vittori, B. B., Solano-Gutiérrez, J. S., Gee, R. R. F., Štepihar, D., Sanchez, M. C. H., Uhan, S., Koren, J., Snoj, L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.20.760599
Turabi, K. S., Sardarni, U. K., Ankenbauer, K. E., Torbit, S. M., Taranto, C. P., Dash, S., Meade, A., Cephas, A., Klute, K. A., di Magliano, M. P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.20.760559
Hamidi, A. A., Moaven, O., Mahmoudian, R. A., & Abbaszadegan, M. R. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00849-2
Rat sarcoma inhibitors in and beyond gynecologic malignancies
Dwabe, S., Samaeekia, R., & Cristea, M. C. (2026) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000001158
Preoperative gemcitabine versus 5-FU–based chemotherapy: is there a standard of care?
Ilson, D. H. (2026) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djag346
Liu, Y., & Wang, M. (2026) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2026.10.003
Monfared, Y. K., Haj‐Mirzaian, A., Li, D., Krishna, S., Heidari, P., Strickland, M. R., Qadan, M., Weekes, C. D., & Esfahani, S. A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18111361
Development of a Core Outcome Set for Pancreatic Cancer Rehabilitation – A Study Protocol
Brennan, L., Smith, V. A., Kirkham, J. J., Lucey, N., Sheill, G., Deasy, P., Doran, P., O'Kane, G. M., Griffin, O. M., & O’Neill, L. M. (2026) · HRB Open Research · doi:10.12688/hrbopenres.14558.1
The unfulfilled promise of effective cancer medicines priced beyond reach
Booth, C. M., Taylor, C. W., Jackson, C. G. C. A., Tregear, M., Sengar, M., Wilson, B. E., Tannock, I. F., Gyawali, B., Berry, S. R., Verduzco-Aguirre, H. C., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00533-4
Zheng, J., Chi, L., & Guo, Y. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101503
Systemtherapie des Pankreaskarzinoms: aktueller Standard und personalisierte Therapieansätze
Schürmann, H., & Siveke, J. T. (2026) · Die Onkologie · doi:10.1007/s00761-026-02031-z
MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer
Rajesh, C., Sagar, S., Huang, Y., Mundry, C. S., Chaitankar, V., Shah, O. S., Sumeet, C., Caffrey, T., O’Connell, K. A., Swanson, B., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218927
ASCO 2026: ключові дослідження
Л.І., Г. (2026) · Clinical Oncology · doi:10.32471/clinicaloncology.2663-466x.36760
The Future of Precision Hepatopancreatobiliary Surgery—Beyond Anatomy
Aziz, H., & Pawlik, T. M. (2026) · JAMA Surgery · doi:10.1001/jamasurg.2026.4783
Wenthe, J., Wiktorin, H. G., Hahn, A., Naseri, S., Calandigary, A., White, L. A., Sandin, L. C., Nordström, C. B., Mielke, S., Lövgren, T., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-016908
Rethinking radiation therapy in the era of RAS inhibition for pancreatic cancer
Chuong, M. D., & O'Reilly, E. M. (2026) · The Oncologist · doi:10.1093/oncolo/oyag433
Self-citationFatima, F., Javed, M. A., Mirza, A., Ahmad, S., Shahzad, Z., & Murad, A. (2026) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001387
Intrinsic resistance to KRAS inhibition: Interfering with interferon
Miguel‐López, B., & Drosten, M. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.10.001
The Price of Hope—A Brazilian Oncologist’s 4 Encounters With Daraxonrasib
Peixoto, R. D. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2026.4380
Pancreatic cancer: The RAS paradigm shift
Soff, S. P., & O'Reilly, E. M. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1005283
Self-citation
Metadata
- Authors
- O’Reilly, E. M., Wainberg, Z. A., Hendifar, A. E., Borad, M. J., Pietrantonio, F., Pant, S., Hammel, P., Cremolini, C., Manji, G. A., Oberstein, P. E., Garrido-Laguna, I., Springfeld, C., Azad, N. S., Ueno, M., Chui, S. Y., Zhang, Y., Patel, H., Lee, Y., Salman, Z., & Wolpin, B. M.
- Affiliations
- Memorial Sloan Kettering Cancer Center, New York
- University of California, Los Angeles (US)
- Cedars-Sinai Medical Center (US)
- Mayo Clinic in Arizona (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- The University of Texas MD Anderson Cancer Center (US)
- Université Paris-Saclay (FR)
- University of Pisa (IT)
- Columbia University Irving Medical Center (US)
- NYU Langone Health (US)
- Huntsman Cancer Institute, University of Utah, Salt Lake City
- University Hospital Heidelberg (DE)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Kanagawa Cancer Center (JP)
- Revolution Medicines (United States) (US)
- Dana-Farber Cancer Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2026-07-23
- Volume
- 395
- Issue
- 4
- Pages
- 325-337
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W7162952636
- Cited by
- 147
- References
- 30
- Citations by year
- 2026: 147
- FWCI
- 431.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Revolution Medicines
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- daraxonrasib, metastatic pancreatic ductal adenocarcinoma, RAS inhibitors, previously treated patients, chemotherapy comparison, overall survival, progression-free survival, adverse events, treatment discontinuation
- MeSH terms
- Gain of Function Mutation, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Piperazines, Quality of Life, Time Factors, ras Proteins, Carcinoma, Pancreatic Ductal, Kaplan-Meier Estimate, Response Evaluation Criteria in Solid Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.